Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK1 | P28482 | 3/20 | 0.35 |
| ▸ | PDE4D | Q08499 | 2/20 | 0.32 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL516176 | 1.00 | MAPK1 (0.35) | MAPK1PDE4DPIK3CAKMT2AADORA3 | |
| SCHEMBL20851935 | 1.00 | MAPK1 (0.35) | MAPK1PDE4DPIK3CAKMT2AADORA3 | |
| SCHEMBL15976749 | 0.90 | KMT2A (0.33) | KMT2AADORA3 | |
| SCHEMBL22734104 | 0.88 | KMT2A (0.40) | KMT2AADORA3 | |
| SCHEMBL22734115 | 0.88 | KMT2A (0.38) | KMT2AADORA3 | |
| SCHEMBL22734110 | 0.86 | — | — | |
| SCHEMBL22734105 | 0.86 | KMT2A (0.43) | PDE4DKMT2AADORA3 | |
| SCHEMBL8061460 | 0.84 | KCNH2 (0.36) | MAPK1PDE4DPIK3CA | |
| SCHEMBL10283145 | 0.84 | PIK3CA (0.36) | MAPK1PDE4DPIK3CA | |
| SCHEMBL31474619 | 0.84 | ADORA3 (0.32) | KMT2AADORA3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 31 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260008788-A1 | AZA-FUSED RING COMPOUND, PREPARATION METHOD THEREFOR, AND USE THEREOF IN MEDICINE | SUZHOU ARK BIOPHARMACEUTICAL CO LTD (CN) | 2026-01-08 | — | — | US | disclosed |
| EP-4674852-A1 | PREPARATION METHOD FOR AND USE OF DIHYDROTHIENOPYRIMIDINE DERIVATIVE | Innovstone Therapeutics Limited (CN) | 2026-01-07 | — | — | EP | disclosed |
| EP-4596554-A1 | AZA-FUSED RING COMPOUND, PREPARATION METHOD THEREFOR, AND USE THEREOF IN MEDICINE | Suzhou Arkbiopharmaceutical Co., Ltd. (CN) | 2025-08-06 | — | — | EP | disclosed |
| WO-2025067168-A1 | AZA FUSED RING COMPOUND, PREPARATION METHOD THEREFOR AND USE THEREOF | 苏州爱科百发生物医药技术有限公司 | 2025-04-03 | — | — | WO | disclosed |
| CN-119698422-A | Aza condensed ring compound, preparation method and medical application thereof | 苏州爱科百发生物医药技术有限公司 | 2025-03-25 | — | — | CN | disclosed |
| EP-3684775-B1 | SUBSTITUTED DIHYDROTHIENOPYRIMIDINES AND THEIR USE AS PHOSPHODIESTERASE INHIBITORS | UNION THERAPEUTICS AS (DK) | 2024-11-20 | — | — | EP | disclosed |
| CN-118871444-A | Preparation method and application of dihydro-thienopyrimidine derivative | 上海翊石医药科技有限公司 | 2024-10-29 | — | — | CN | disclosed |
| WO-2024179493-A1 | PREPARATION METHOD FOR AND USE OF DIHYDROTHIENOPYRIMIDINE DERIVATIVE | 上海翊石医药科技有限公司 | 2024-09-06 | — | — | WO | disclosed |
| CN-111712503-B | Substituted tetrahydropyran dihydro-thienopyrimidines and their use as phosphodiesterase inhibitors | 联合疗法公司 | 2024-04-09 | — | — | CN | disclosed |
| US-11866445-B2 | Substituted dihydrothienopyrimidines and their use as phosphodiesterase inhibitors | UNION therapeutics A/S (DK) | 2024-01-09 | — | — | US | disclosed |
| EP-3724195-A1 | SUBSTITUTED TETRAHYDROPYRAN DIHYDROTHIENOPYRIMIDINES AND THEIR USE AS PHOSPHODIESTERASE INHIBITORS | Leo Pharma A/S (DK) | 2020-10-21 | — | — | EP | disclosed |
| EP-3724194-A1 | SUBSTITUTED AZETIDINE DIHYDROTHIENOPYRIMIDINES AND THEIR USE AS PHOSPHODIESTERASE INHIBITORS | Leo Pharma A/S (DK) | 2020-10-21 | — | — | EP | disclosed |
| CN-111712503-A | Substituted tetrahydropyran dihydrothienopyrimidines and their use as phosphodiesterase inhibitors | 利奥制药有限公司 | 2020-09-25 | — | — | CN | disclosed |
| CN-111712502-A | Substituted azetidine dihydrothienopyrimidines and their use as phosphodiesterase inhibitors | 利奥制药有限公司 | 2020-09-25 | — | — | CN | disclosed |
| US-20200239493-A1 | SUBSTITUTED DIHYDROTHIENOPYRIMIDINES AND THEIR USE AS PHOSPHODIESTERASE INHIBITORS | UNION therapeutics A/S (DK) | 2020-07-30 | — | — | US | disclosed |
| EP-3684775-A1 | SUBSTITUTED DIHYDROTHIENOPYRIMIDINES AND THEIR USE AS PHOSPHODIESTERASE INHIBITORS | Leo Pharma A/S (DK) | 2020-07-29 | — | — | EP | disclosed |
| WO-2019115774-A1 | SUBSTITUTED AZETIDINE DIHYDROTHIENOPYRIMIDINES AND THEIR USE AS PHOSPHODIESTERASE INHIBITORS | LEO PHARMA A/S (DK) | 2019-06-20 | — | — | WO | disclosed |
| WO-2019115775-A1 | SUBSTITUTED TETRAHYDROPYRAN DIHYDROTHIENOPYRIMIDINES AND THEIR USE AS PHOSPHODIESTERASE INHIBITORS | LEO PHARMA A/S (DK) | 2019-06-20 | — | — | WO | disclosed |
| WO-2019057806-A1 | SUBSTITUTED DIHYDROTHIENOPYRIMIDINES AND THEIR USE AS PHOSPHODIESTERASE INHIBITORS | LEO PHARMA A/S (DK) | 2019-03-28 | — | — | WO | disclosed |
| WO-2019057806-A1 | SUBSTITUTED DIHYDROTHIENOPYRIMIDINES AND THEIR USE AS PHOSPHODIESTERASE INHIBITORS | LEO PHARMA A/S (DK) | 2019-03-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260008788-A1 | AZA-FUSED RING COMPOUND, PREPARATION METHOD THEREFOR, AND USE THEREOF IN MEDICINE | PDE4B, PDE4A, CYP4A11 | MAPK1 2674/4885PDE4D 5/4885PIK3CA 909/4885 |
| US-20200239493-A1 | SUBSTITUTED DIHYDROTHIENOPYRIMIDINES AND THEIR USE AS PHOSPHODIESTERASE INHIBITORS | PDE4A, PDE7A, PDE12 | MAPK1 2254/4885PDE4D 11/4885PIK3CA 978/4885 |
| US-11866445-B2 | Substituted dihydrothienopyrimidines and their use as phosphodiesterase inhibitors | PDE4A, PDE7A, PDE12 | MAPK1 2254/4885PDE4D 11/4885PIK3CA 978/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.